N6-methyladenosine–mediated up-regulation of ARRB2 regulates intrahepatic cholangiocarcinoma malignant progression and pemigatinib resistance through MAPK and Hippo signaling pathways

Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, et al. Cholangiocarcinoma. Nat Rev Dis Primers. 2021;7:65.

Google Scholar 

Nataliya R, Gregory JG. Cholangiocarcinoma. Lancet. 2014;383:2168–79.

Google Scholar 

Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin. 2023;73:198–222.

Google Scholar 

Gravely AK, Vibert E, Sapisochin G. Surgical treatment of intrahepatic cholangiocarcinoma. J Hepatol. 2022;77:865–7.

Google Scholar 

Borad MJ, Paine A, Wacheck V, He Y, Kazerooni R, Salimi T, et al. Indirect treatment comparison of futibatinib with chemotherapy and pemigatinib in cholangiocarcinoma with FGFR2 fusions/rearrangements. J Clin Oncol. 2022;40:440.

Google Scholar 

Liu Z, Liu J, Chen T, Wang Y, Shi A, Li K, et al. Wnt-TCF7-SOX9 axis promotes cholangiocarcinoma proliferation and pemigatinib resistance in a FGF7-FGFR2 autocrine pathway. Oncogene. 2022;41:2885–96.

Google Scholar 

Gritsina G, Fong KW, Lu X, Lin Z, Xie W, Agarwal S, et al. Chemokine receptor CXCR7 activates Aurora Kinase A and promotes neuroendocrine prostate cancer growth. J Clin Investig. 2023;133:e166248.

Google Scholar 

Wu Y, Hu Y, Wang B, Li S, Ma C, Liu X, et al. Dopamine uses the DRD5-ARRB2-PP2A signaling axis to block the TRAF6-mediated NF-kappaB pathway and suppress systemic inflammation. Mol Cell. 2020;78:42–56 e6.

Google Scholar 

Wei X, Wu D, Li J, Wu M, Li Q, Che Z, et al. Myeloid beta-arrestin 2 depletion attenuates metabolic dysfunction-associated steatohepatitis via the metabolic reprogramming of macrophages. Cell Metab. 2024;36:2281–97 e7.

Google Scholar 

Huang F, Liu Z, Song Y, Wang G, Shi A, Chen T, et al. Bile acids activate cancer-associated fibroblasts and induce an immunosuppressive microenvironment in cholangiocarcinoma. Cancer Cell. 2025;43:1460–75 e10.

Google Scholar 

Liu J, Li S, Zhou H, Wang M, Zhang C, Tian C, et al. REG3A promotes gemcitabine resistance in pancreatic cancer via the GPR54/ARRB2/ERK1/2 ligand-directed signaling pathway. Biochem Pharmacol. 2025;242:117322.

Google Scholar 

Wang Y, Sun Y, Zhao W, Zhang J, Wang X, Hu F, et al. Regulatory mechanisms of the Hippo/YAP axis by G-protein-coupled estrogen receptor in gastric signet-ring cell carcinoma. Neoplasia. 2025;67:101199.

Google Scholar 

Xia L, Chen X, Yang J, Zhu S, Zhang L, Yin Q, et al. Long non-coding RNA-PAICC promotes the tumorigenesis of human intrahepatic cholangiocarcinoma by increasing YAP1 transcription. Front Oncol. 2020;10:595533.

Google Scholar 

Liu L, Li H, Hu D, Wang Y, Shao W, Zhong J, et al. Insights into N6-methyladenosine and programmed cell death in cancer. Mol Cancer. 2022;21:32.

Google Scholar 

Zhou Z, Lv J, Yu H, Han J, Yang X, Feng D, et al. Mechanism of RNA modification N6-methyladenosine in human cancer. Mol Cancer. 2020;19:104.

Google Scholar 

Huang W, Chen TQ, Fang K, Zeng ZC, Ye H, Chen YQ. N6-methyladenosine methyltransferases: functions, regulation, and clinical potential. J Hematol Oncol. 2021;14:117.

Google Scholar 

Li Q, Ni Y, Zhang L, Jiang R, Xu J, Yang H, et al. HIF-1alpha-induced expression of m6A reader YTHDF1 drives hypoxia-induced autophagy and malignancy of hepatocellular carcinoma by promoting ATG2A and ATG14 translation. Signal Transduct Target Ther. 2021;6:76.

Google Scholar 

Fan B, Malato Y, Calvisi DF, Naqvi S, Razumilava N, Ribback S, et al. Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Investig. 2012;122:2911–5.

Google Scholar 

Hoy SM. Pemigatinib: first approval. Drugs. 2020;80:923–9.

Google Scholar 

Sadida HQ, Abdulla A, Marzooqi SA, Hashem S, Macha MA, Akil ASA, et al. Epigenetic modifications: Key players in cancer heterogeneity and drug resistance. Transl Oncol. 2024;39:101821.

Google Scholar 

Karami Fath M, Azargoonjahromi A, Kiani A, Jalalifar F, Osati P, Akbari Oryani M, et al. The role of epigenetic modifications in drug resistance and treatment of breast cancer. Cell Mol Biol Lett. 2022;27:52.

Google Scholar 

Zhang Z, Zhang C, Yang Z, Zhang G, Wu P, Luo Y, et al. m(6)A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer. J Hematol Oncol. 2021;14:190.

Google Scholar 

Wang L, Katipally RR, Liang HL, Yang K, Pitroda SP, He C, et al. RNA m(6)A methylation and MDSCs: Roles and therapeutic implications for radiotherapy. Med. 2023;4:863–74.

Google Scholar 

Li X, Ma S, Deng Y, Yi P, Yu J. Targeting the RNA m(6)A modification for cancer immunotherapy. Mol Cancer. 2022;21:76.

Google Scholar 

Li Y, Wang NX, Yin C, Jiang SS, Li JC, Yang SY. RNA editing enzyme ADAR1 regulates METTL3 in an editing-dependent manner to promote breast cancer progression via METTL3/ARHGAP5/YTHDF1 axis. Int J Mol Sci. 2022;23:9656.

Wang L, Yang Q, Zhou Q, Fang F, Lei K, Liu Z, et al. METTL3-m(6)A-EGFR-axis drives lenvatinib resistance in hepatocellular carcinoma. Cancer Lett. 2023;559:216122.

Google Scholar 

Yang R, Yang C, Su D, Song Y, Min J, Qian Z, et al. METTL3-mediated RanGAP1 promotes colorectal cancer progression through the MAPK pathway by recruiting YTHDF1. Cancer Gene Ther. 2024;31:562–73.

Google Scholar 

Chan LK, Ho DW, Kam CS, Chiu EY, Lo IL, Yau DT, et al. RSK2-inactivating mutations potentiate MAPK signaling and support cholesterol metabolism in hepatocellular carcinoma. J Hepatol. 2021;74:360–71.

Google Scholar 

Bahar ME, Kim HJ, Kim DR. Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct Target Ther. 2023;8:455.

Google Scholar 

Driskill JH, Pan D. Control of stem cell renewal and fate by YAP and TAZ. Nat Rev Mol Cell Biol. 2023;24:895–911.

Google Scholar 

Huang LS, Hong Z, Wu W, Xiong S, Zhong M, Gao X, et al. mtDNA activates cGAS signaling and suppresses the YAP-mediated endothelial cell proliferation program to promote inflammatory injury. Immunity. 2020;52:475–86 e5.

Google Scholar 

Yosefzon Y, Soteriou D, Feldman A, Kostic L, Koren E, Brown S, et al. Caspase-3 regulates YAP-dependent cell proliferation and organ size. Mol Cell. 2018;70:573–87 e4.

Google Scholar 

Moya IM, Halder G. Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine. Nat Rev Mol Cell Biol. 2019;20:211–26.

Google Scholar 

Sun WY, Hu SS, Wu JJ, Huang Q, Ma Y, Wang QT, et al. Down-regulation of beta-arrestin2 promotes tumour invasion and indicates poor prognosis of hepatocellular carcinoma. Sci Rep. 2016;6:35609.

Google Scholar 

Yang Y, Guo Y, Tan S, Ke B, Tao J, Liu H, et al. beta-Arrestin1 enhances hepatocellular carcinogenesis through inflammation-mediated Akt signalling. Nat Commun. 2015;6:7369.

Google Scholar 

Saleh M, Barve M, Subbiah V, Papadopoulos KP, Morgensztern D, Mettu NB, et al. Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies. ESMO Open. 2024;9:103625.

Google Scholar